详情页 - 河北医科大学第四医院机构库

当前位置：首页 > 详情页

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

3| 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究参与人：

研究单位： [1]Shanghai JMT-Bio Inc. [2]The Fourth Hospital of Hebei Medical University Shijiazhuang, Hebei, China, 050000 [3]Chinese Pla General Hospital Beijing, China [4]Hunan Cancer Hospital Changsha, China [5]West China Hospital of Sichuan University Chengdu, China [6]Fujian Cancer Hospital Fuzhou, China [7]Zhejiang Cancer Hospital Hangzhou, China [8]Jiangsu Province Hospital of Chinese Medicine Nanjing, China [9]Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School Nanjing, China [10]Shanghai Chest Hospital, Shanghai Jiaotong University Shanghai, China [11]Shanxi Bethune Hospital (Shanxi Academy of Medical Sciences) Taiyuan, China [12]Shanxi Province Cancer Hospital Taiyuan, China [13]Union Hospital, affiliated with TongJi Medical College, HuaZhong University of Science and Technology Wuhan, China [14]Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China, 510060

研究目的：

This study is a Phase Ib, open label, multi-center study of to evaluate the safety and efficacy of JMT101 combined with EGFR-TKIs (Afatinib or Osimertinib) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.